Feature | September 11, 2013

Third TAVI Vendor Enters U.S. Clinical Trials

First patient enrolls in SALUS Trial of Direct Flow Medical transcatheter aortic valve

September 11, 2013 — Direct Flow Medical Inc. announced the first patient enrollment in the U.S. SALUS clinical trial. The trial will study the Direct Flow Medical Transcatheter Aortic Heart Valve System, which encompasses a distinctive transcatheter aortic heart valve with a metal-free frame and flexible, low-profile delivery system designed to eliminate aortic regurgitation. The device is intended to improve the long-term survivability of aortic stenosis patients by resolving the clinical issues associated with current commercial valves.

The SALUS Trial is a non-randomized, multi-center, core lab-adjudicated, investigational device exemption (IDE) trial of 30 patients being conducted at six U.S. clinical sites. Principal investigators for the SALUS Trial are Murat Tuzcu, M.D., vice chairman of the department of cardiology, Cleveland Clinic, and Patrick McCarthy, M.D., director of the Bluhm Cardiovascular Institute and chief of cardiac surgery, Northwestern Memorial Hospital.

William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital performed the first Direct Flow Medical case in the United States.

"The team at Henry Ford Hospital is pleased to be the first in the U.S. to implant the Direct Flow Medical heart valve," said O'Neill. "A device that is repositionable and able to pass through smaller diameter blood vessels is an important advance in the next generation of transcatheter aortic valve replacement (TAVR) systems. This could help patients who have not been good candidates for earlier TAVR devices."

The Direct Flow Medical Transcatheter Aortic Valve System is designed to achieve optimal outcomes by enabling in-situ hemodynamic assessment after the valve is fully deployed in the native valve annulus, as well as repositioning with full distal, proximal and planar control, or retrieval, if required. The system avoids rapid pacing of the heart during deployment, and does not require post-dilatation following placement, minimizing the risk of hemodynamic stress for patients.

The Direct Flow Medical System received the CE mark in January 2013 and is currently available commercially in Europe.

For more information: www.directflowmedical.com

Related Content

The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1 to Gyrus Capital and Corcym..

The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1.

News | Heart Valve Technology | June 02, 2021
June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its...
If MitraClip Fails 95 Percent of Patients Will Need Full Surgical Valve Replacement according to a late-breaking study at the AATS 2021 meeting. #AATS2021

If MitraClip fails and a surgical repair is required, a late-breaking study presented at the 2021 AATS meeting showed 95 percent of patients will require a full surgical valve replacement.

News | Heart Valve Technology | May 04, 2021
May 4, 2021 – A new study, presented at the 2021 American Association f...
University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. This can be implanted in pediatric patients with congenital heart diseas. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

News | Heart Valve Technology | March 18, 2021
March 18, 2020 — A groundbreaking new study led by University of Minnesota Twin Cities researchers from both the Coll
Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session.
News | Heart Valve Technology | February 04, 2021
February 4, 2021 — Transcatheter aortic valve replacement (TAVR) has historically only been used with caution in the
Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) so the company to initiate a U.S. clinical study of its Tria biopolymer mitral surgical heart valve.
News | Heart Valve Technology | December 14, 2020
December 14, 2020 - Foldax Inc. today announced that the U.S.

The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients. 

Feature | Heart Valve Technology | November 17, 2020
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, mor
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | November 17, 2020 | Dave Fornell, Editor
November 17, 2020 — Boston Scientific Corp.